Released Mar 27, 2025, after the close
10-K filed Mar 27, 2025, 86 days after period end · 0000950170-25-046125
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$52.00K$52.00K derived−76.7% vs Q4 2023−20.0% vs Q3 2024
Net Income-$20.89M-$20.89M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$21,725,000N/M
Operating Cash Flowderived-$23,401,000N/M
Margins · derived
Operating margin-41778.8%
Net margin-40169.2%
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $52.00K | $223.00K | $278.00K | — |
| Net Income | -$20.89M | $51.21M | $26.79M | -$29.30M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR